Skip to main content
ROVI Subsidiaries
Spain
Germany
France
Italy
Poland
Portugal
United Kingdom
Language
Spanish
Spanish
English
English
English
Español
Home
ROVI
History
Group structure
Business units
International expansion
Strategy
Licenses
Contact
Products
Prescription Pharmaceuticals
Hospital Products
Manufacturing
CDMO
Own product Manufacturing
R&D
Shareholders and Investors
The share
Investor's Calendar
News
Financial and Business Information
CMNV Communications
ESG
Corporate Governance
Telematic assistance access
Prior Registration On-Line Attendance
On-Line Attendance
Sustainability
Responsible governance
Commitment to people
Environmental Commitment
Ethics Channel
Media
FAQS
News
ROVI up to date
Contact
Work with Us
TELEMATIC ASSISTANCE ACCESS
Home
News
First quarter 2019 results presentation
Operating income, growth figures, profitability and how our products have behaved
Wed, 08/05/2019 - 12:15
0 min
Español
technology-g9d73178da_640.jpg
Download related document
Select rating
Give First quarter 2019 results presentation 1/5
Give First quarter 2019 results presentation 2/5
Give First quarter 2019 results presentation 3/5
Give First quarter 2019 results presentation 4/5
Give First quarter 2019 results presentation 5/5
No votes yet
Related
9M 2018 Results presentation
0 min
06/11/2018
ROVI announces an agreement with Biogaran for the marketing of its enoxaparin...
0 min
20/09/2018
ROVI has commenced the marketing of its enoxaparin biosimilar in Spain
0 min
19/09/2018
See More
Email
Facebook
Twitter
LinkedIn
technology-g9d73178da_640.jpg